Basilea Pharmaceutica AG (SWX:BSLN)
Switzerland
· Delayed Price · Currency is CHF 52.00
+0.30 (0.58%)
Aug 15, 2025, 5:30 PM CET
Basilea Pharmaceutica AG Revenue
In the year 2024, Basilea Pharmaceutica AG had annual revenue of 208.54M CHF with 32.30% growth. Basilea Pharmaceutica AG had revenue of 132.25M in the half year ending December 31, 2024, with 46.75% growth.
Revenue
208.54M
Revenue Growth
+32.30%
P/S Ratio
3.06
Revenue / Employee
1.27M
Employees
164
Market Cap
637.94M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 208.54M | 50.91M | 32.30% |
| Dec 31, 2023 | 157.63M | 9.87M | 6.68% |
| Dec 31, 2022 | 147.77M | -357.00K | -0.24% |
| Dec 31, 2021 | 148.12M | 20.49M | 16.06% |
| Dec 31, 2020 | 127.63M | -6.75M | -5.02% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Roche Holding AG | 63.49B |
| Novartis AG | 43.89B |
| Lonza Group AG | 7.09B |
| Alcon | 8.77B |
| Galderma Group AG | 3.73B |
| Sandoz Group AG | 8.42B |
| Straumann Holding AG | 2.50B |
| Sonova Holding AG | 3.87B |
Basilea Pharmaceutica AG News
- 3 months ago - Assessment of the 14-Alpha Demethylase Inhibitors Pipeline Landscape 2025, Featuring Insights Into Oteseconazole (Mycovia Pharmaceuticals) and Isavuconazonium (Basilea Pharmaceutica) - GlobeNewsWire
- 4 months ago - Strong sales for Cresemba® (isavuconazole) in Japan trigger second milestone payment from Asahi Kasei Pharma to Basilea - GlobeNewsWire
- 6 months ago - Basilea Pharmaceutica Ltd (XSWX:BSLN) Full Year 2024 Earnings Call Highlights: A Year of Robust ... - GuruFocus
- 6 months ago - Full Year 2024 Basilea Pharmaceutica AG Allschwil Earnings Call Transcript - GuruFocus
- 6 months ago - Basilea projects CHF220M in 2025 revenue with key pipeline advancements and U.S. launch of Zevtera - Seeking Alpha
- 6 months ago - Basilea Pharmaceutica AG (BPMUF) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 6 months ago - Basilea Pharmaceutica AG 2024 Q4 - Results - Earnings Call Presentation - Seeking Alpha
- 6 months ago - Basilea Pharmaceutica GAAP EPS of CHF5.83, revenue of CHF208.5M; initiates FY25 outlook - Seeking Alpha